Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma

[1]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[2]  L. Bubendorf,et al.  Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer , 2011, Journal of Translational Medicine.

[3]  T. Fry,et al.  Harnessing the biology of IL-7 for therapeutic application , 2011, Nature Reviews Immunology.

[4]  Marco Erreni,et al.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer , 2011, Cancer Microenvironment.

[5]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[6]  Chien-Hsing Lee,et al.  Intratumoral macrophage counts correlate with tumor progression in colorectal cancer , 2010, Journal of surgical oncology.

[7]  Giacomo Puppa,et al.  TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. , 2010, Archives of pathology & laboratory medicine.

[8]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[9]  J. Monson,et al.  Differences in cytokine levels due to gender in colorectal cancer patients. , 2010, Cytokine.

[10]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[11]  J. Steinke,et al.  Immunologic messenger molecules: cytokines, interferons, and chemokines. , 2010, The Journal of allergy and clinical immunology.

[12]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.

[13]  C. Heldin,et al.  PDGF and vessel maturation. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[14]  H. Knüpfer,et al.  Serum interleukin-6 levels in colorectal cancer patients—a summary of published results , 2010, International Journal of Colorectal Disease.

[15]  R. DuBois,et al.  The role of chemokines in intestinal inflammation and cancer. , 2009, Current opinion in pharmacology.

[16]  C. Mackall,et al.  Modulating T‐cell homeostasis with IL‐7: preclinical and clinical studies , 2009, Journal of internal medicine.

[17]  D. McMillan,et al.  Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. , 2009, European journal of cancer.

[18]  H. Shantha Kumara,et al.  Platelet-Derived Growth Factor (Subtype BB) Is Elevated in Patients with Colorectal Carcinoma , 2009, Diseases of the colon and rectum.

[19]  V. Colantuoni,et al.  Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. , 2009, Human pathology.

[20]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[21]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[22]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[23]  G. Cui,et al.  Polarization of cytokine profile from Th1 into Th2 along colorectal adenoma-carcinoma sequence: implications for the biotherapeutic target? , 2008, Inflammation & allergy drug targets.

[24]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[25]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  V. O. Frick,et al.  Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. , 2007, World journal of gastroenterology.

[27]  C. Parish,et al.  Th2-mediated anti-tumour immunity: friend or foe? , 2007, Tissue antigens.

[28]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[29]  A. Darzi,et al.  Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer , 2007, Clinical & Experimental Metastasis.

[30]  A. Darzi,et al.  The Risk of Cancer in Patients with Crohn’s Disease , 2007, Diseases of the colon and rectum.

[31]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[32]  Takashi Ueda,et al.  Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis , 1994, Journal of Gastroenterology.

[33]  J. Melkko,et al.  Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.

[34]  H. Cross,et al.  Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. , 2005, European journal of cancer.

[35]  K. Wada,et al.  Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma , 2005, Gut.

[36]  M. Nowacki,et al.  Clinical Significance of Serum Cytokine Measurements in Untreated Colorectal Cancer Patients: Soluble Tumor Necrosis Factor Receptor Type I – An Independent Prognostic Factor , 2005, Tumor Biology.

[37]  T. Fry,et al.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. , 2005, The Journal of clinical investigation.

[38]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[39]  R. Salgado,et al.  Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma , 2004, Cancer.

[40]  N. Konishi,et al.  Serum monocyte chemoattractant protein-1 in patients with postoperative infectious complications from gastrointestinal surgery for cancer , 2004, World Journal of Surgery.

[41]  Yuan‐Chang Chung,et al.  Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.

[42]  H. Tonouchi,et al.  Profile of Monocyte Chemoattractant Protein-1 Circulating Levels in Gastric Cancer Patients , 2002, Scandinavian journal of gastroenterology.

[43]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[44]  M. Duffy,et al.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.

[45]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[46]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[47]  V. Kosma,et al.  Prognostic value of tumour‐infiltrating lymphocytes (TILs) in colorectal cancer , 1997, The Journal of pathology.

[48]  C. Casciani,et al.  Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression , 1996, Cancer Immunology, Immunotherapy.

[49]  M. Burdick,et al.  Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. , 1995, Biochemical and biophysical research communications.

[50]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[51]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[52]  J. Burke,et al.  Carcinoma of the colon and rectum. , 1962, The New England journal of medicine.

[53]  G. Miller.  Carcinoma of the Colon and Rectum. , 1942, Canadian Medical Association journal.